Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Oral SYN-004 on Ceftriaxone PK in Subjects with Ileostomy
NCT02419001Phase 2Completed
- Sponsor
- Theriva Biologics
- Start
- Mar 2015
- Primary completion
- Sep 2015
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of ribaxamase in Clostridioides difficile infection (CDI), sponsored by Theriva Biologics. Started Mar 2015; status: completed.
02
Drugs
ribaxamase
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02419001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419001.